SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

SNDL Inc.NASDAQ: SNDL

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables outflow grows to CA$0

Q1 FY2026 accounts payables was CA$0, compared with CA$0 a year earlier. Trailing-twelve-month accounts payables was CA$0.

Context

  • Accounts payables amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Accounts payables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0— QoQ
Last fiscal yearDec 2025
CA$0— YoY
LTMMar 2026
CA$0— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

CAD · from the cash flow

Latest · FY2025
0 CAD
Year-over-year change
—

Accounts Payables vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Accounts payables amounts to 0.0% of revenue for SNDL, versus a peer median of 0.9%.
SNDL Competitors
Accounts Payables for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$17.4M USD-51.7%-15.7%2.6%
SIGASIGA Technologies, Inc.LTM Mar 2026$7M USD-186.0%—7.5%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$3.59M USD-108.2%+55.1%0.9%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.39M USD+1225.9%——
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$3.23M USD+147.7%+135.7%—
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$2.48M USD-163.4%+27.1%1.1%
EOLSEvolus, Inc.LTM Mar 2026$2.23M USD-153.0%+118.5%0.7%
CMPSCOMPASS Pathways plcLTM Mar 2026$1.81M USD+305.3%-6.6%—
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$355K USD-110.4%+128.7%0.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$35K USD-92.7%—0.0%
SNDLSNDL Inc.LTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding SNDL) —-100.4%+55.1%0.9%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(230.18M)(372.43M)(176.55M)(96.2M)(15.77M)
Depreciation & Amortization9.6M47.32M64.95M56.71M56.27M
Deferred Income Tax(2.27M)(7.34M)0(9.41M)0
Stock-Based Compensation12.31M9.67M15.4M20.04M13.91M
Change in Working Capital(1.53M)(22.07M)(32.88M)(7.45M)1.43M
Accounts Receivables00000
Inventory16.98M7.01M000
Accounts Payables00000
Other Working Capital(18.51M)(29.09M)(32.88M)(7.45M)1.43M
Other Non-Cash Items56.64M338.14M112.43M91.22M15.08M
Operating Cash Flow(155.44M)(6.71M)(16.65M)54.91M70.92M
Capital Expenditures(3.79M)(10.86M)(7.93M)(11.02M)(12.81M)
Acquisitions (Net)(478.34M)(147.78M)(21.39M)(39.48M)(3M)
Purchases of Investments(24.21M)(75.6M)(732K)0(16.41M)
Sales of Investments10.68M00045.58M
Other Investing Activities(612K)4.07M5.15M65.85M4.1M
Investing Cash Flow(496.28M)(230.16M)(24.82M)17.76M17.45M
Debt Repayment(10.36M)(37.69M)(41.01M)(36.95M)(39.25M)
Common Stock Issued1.06B22K000
Common Stock Repurchased0(13.39M)(1.54M)(13.28M)(15.35M)
Dividends Paid00000
Other Financing Activities97.65M9.27M(531K)871K106K
Financing Cash Flow1.15B(41.79M)(43.08M)(49.36M)(54.49M)
Effect of Forex Changes(9K)0000
Net Change in Cash497.88M(278.67M)(84.55M)23.32M33.88M
Free Cash Flow(159.23M)(17.57M)(24.58M)43.9M58.11M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.